Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results

Syndax Pharmaceuticals (NASDAQ:SNDX) posted its quarterly earnings data on Thursday. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.14), FiscalAI reports. The firm had revenue of $68.73 million during the quarter, compared to the consensus estimate of $64.75 million. Syndax Pharmaceuticals had a negative net margin of 165.37% and a negative return on equity of 175.50%. The company’s revenue for the quarter was up 792.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.10) earnings per share.

Here are the key takeaways from Syndax Pharmaceuticals’ conference call:

• Syndax reported strong commercial momentum for Revuforj, with $124.8M net revenue in 2025, a 38% sequential increase in Q4, ~35% prescription growth, and rapid uptake following the NPM1 label expansion.
• The Niktimvo launch outperformed benchmarks—$151.6M partner-reported net sales in 2025 (Syndax recorded $42.4M collaboration revenue) and high persistency, supporting expectations for growing margin contribution over time.
• Pipeline execution is advancing—pivotal frontline trials for revumenib (EVOLVE-2, REVEAL-ND, RAVEN) are enrolling and axatilimab completed Phase 2 enrollment in IPF (MAXPIRe) with top-line data expected in Q4 2026, creating multiple potential near- and mid-term value drivers.
• Financial position and guidance are solid, with total 2025 revenue of $172.4M, $394M in cash and equivalents, and 2026 R&D+SG&A guidance of ~ $400M (ex?noncash stock comp), and management expects to reach profitability without raising additional capital.
• Key commercial assumptions remain uncertain—average Revuforj treatment duration was only ~4–6 months in year one and revenue growth depends on extended durations, higher post?transplant restart rates, and broader combination/frontline uptake that may not materialize as projected.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ SNDX opened at $21.71 on Monday. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. The stock has a fifty day simple moving average of $20.86 and a two-hundred day simple moving average of $18.06. Syndax Pharmaceuticals has a 1-year low of $8.58 and a 1-year high of $22.73. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -6.60 and a beta of 0.42.

Insider Buying and Selling at Syndax Pharmaceuticals

In other news, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the completion of the transaction, the chief executive officer directly owned 491,690 shares of the company’s stock, valued at $10,340,240.70. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Keith A. Goldan sold 3,410 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $71,712.30. Following the completion of the transaction, the chief financial officer owned 140,429 shares of the company’s stock, valued at approximately $2,953,221.87. This represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,063 shares of company stock valued at $628,332 in the last quarter. 4.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of large investors have recently modified their holdings of SNDX. Smartleaf Asset Management LLC raised its position in shares of Syndax Pharmaceuticals by 2,698.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,659 shares of the company’s stock worth $55,000 after acquiring an additional 2,564 shares in the last quarter. Larson Financial Group LLC grew its stake in Syndax Pharmaceuticals by 192.2% in the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after purchasing an additional 1,922 shares during the period. Quantbot Technologies LP bought a new position in Syndax Pharmaceuticals in the third quarter worth $53,000. Lazard Asset Management LLC purchased a new position in Syndax Pharmaceuticals during the second quarter valued at $66,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Syndax Pharmaceuticals by 103.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after buying an additional 4,308 shares in the last quarter.

Key Stories Impacting Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Robust commercial revenue — Syndax reported $68.7M in Q425 and $172.4M for FY2025, driven by product sales; Revuforj (revumenib) net revenue was $44.2M in Q4 (up 38% vs Q3) and Niktimvo (axatilimab?csfr) net revenue was $56.0M in Q4 (up 22% vs Q3). Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue topped expectations and showed large year?over?year growth (Q4 revenue up ~792% YoY), which investors may view as validation of the commercialization ramp. Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress: enrollment completed in the Phase 2 IPF trial of axatilimab with topline data expected in 4Q26 — a clear near?to?mid?term catalyst to monitor. Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst consensus remains constructive — the stock carries an average rating of “Moderate Buy,” which may support sentiment but is not a new catalyst by itself. Syndax Pharmaceuticals, Inc. Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Company hosted an earnings conference call and published slides; these materials provide additional detail on commercialization cadence and guidance drivers. View Press Release / Slide Deck
• Negative Sentiment: EPS missed estimates — Syndax reported a Q4 loss of $0.78 per share versus consensus around ($0.64)–($0.66), signaling continued losses and pressure on near?term profitability. Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Profitability metrics remain weak — the company reported a negative net margin and negative return on equity, underscoring that top?line growth has yet to translate into earnings. Syndax Q4 Earnings Snapshot / Conference Call

Wall Street Analysts Forecast Growth

SNDX has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Monday, December 29th. JPMorgan Chase & Co. decreased their target price on shares of Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Barclays raised their price target on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Stifel Nicolaus set a $45.00 price target on Syndax Pharmaceuticals in a research note on Friday. Finally, UBS Group increased their price objective on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.30.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.